Indian doctors devise score to assess patients' bleeding risk

Image
IANS New Delhi
Last Updated : Oct 21 2013 | 8:41 PM IST

A score has been derived by doctors here to assess the bleeding risk in Indian patients who are on drugs that prevent clotting of blood.

The research by geneticists at the Sir Ganga Ram Hospital here focused on deriving and validating a Genetic Bleeding Risk (GBR) score based on genetic and non-genetic factors associated with bleeding in patients on long-term anti-coagulation (blood clotting) therapy, a release said here Monday.

There are already a few bleeding risk prediction scores available in the world, but most are derived from the white population and more importantly, none have evaluated the predictive significance of genetic risk factors so far, it said.

A substance that prevents clotting of blood, anti-coagulants are being used all over the world since early 1940s for treatment and prevention of thrombosis - clot formation in a blood vessel that obstructs flow and affects various body parts and organs like legs, heart, kidneys, brain and lungs etc.

Despite its common usage, oral anti-coagulant (OAC) therapy is associated with significant bleeding complications.

The study was conducted on 310 patients from departments of vascular surgery, cardiac surgery and neurology from August 2009 to August 2012 at Sir Ganga Ram Hospital here. It took approval from the hospital's ethics board committee and was in accordance with the ethical standards of World Medical Association.

"The report shows that the number of bleeding episodes can be effectively reduced, thus sparing the patients from adverse outcomes and reducing hospital admissions," said Risha Nahar, scientist at the hospital's Centre of Medical Genetics.

"The present study is the first to devise and validate a genetic scoring scheme for predicting bleeding among first time users of oral anti-coagulants," he added.

Both genetic and non-genetic factors (drug-drug interactions, additional medical conditions, age, history of bleeding) are known to contribute towards bleeding or haemorrhage in patients on anti-coagulant therapy.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 21 2013 | 8:34 PM IST

Next Story